Top Performing Drug of 2021 – Xarelto (November Edition)

Active Ingredient: rivaroxaban Strength: 2.5 mg, 10 mg, 15 mg, and 20 mg Dosage Form: Tablets Mechanism of Action: Factor Xa inhibitors First Approval: US (1 Jul 2011), EU (30 Sep 2008) Revenue Analysis of Xarelto1 Xarelto has been an important driver of the revenue generated from the cardiovascular portfolio of Janssen. The blood thinner showed an increase of 4%…

BySenior EditorNovember 24, 2022

THOUGHTSPOT

Neurological Clinical Trial Trends Under Pandemic and Changing Geopolitics

It has been quite evident that the trends in the number of clinical trials associated with neurological conditions have experienced many alterations over the past 8 years (2015-2022). Through our analysis, we came across, that the number of studies increased at a moderate rate between 2015-2019 until it suffered a significant dip in 2020 due…

BySenior EditorNovember 8, 2022

INSIGHTS+

Top Performing Drug of 2021 – Eylea (September Edition)

Active Ingredient: Aflibercept Strength: 2 mg (0.05 mL) Dosage Form: Injection (intravitreal) Mechanism of Action: VEGF-A and PlGF inhibitors First Approval: US (18 Nov 2011), EU (27 Nov 2012) Revenue1 EYLEA net sales represent a significant portion of the total revenues for both Regeneron and Bayer. Both companies jointly commercialize the product Regeneron records net product sales of EYLEA in…

BySenior EditorSeptember 22, 2022

INSIGHTS+

Top Performing Drug of 2021 – Stelara (August Edition)

Active Ingredients: Ustekinumab Strength: 45 mg/0.5 mL or 90 mg/mL (SC), 130 mg/26 mL (IV) Dosage Form: Injection Mechanism of Action: Interleukin 12 & 23 inhibitor First Approval: US (25 Sep, 2009), EU (16 Jan, 2009) Revenue1 Stelara is the leading blockbuster drug of Johnson & Johnson. Stelara contributed 9.7% of the Company's total revenues for 2021. Stelara up took…

BySenior EditorAugust 25, 2022

THOUGHTSPOT

The Emergence of Artificial Intelligence in the Pharmaceutical Industry

The dependability of digital technology has augmented through a variety of industries, including communication, transportation, manufacturing, medical, and pharmaceutical companies. Development in technologies has made it possible to merge medical science with digital platforms, allowing for the individualised delivery of services to a large population, making therapy more effective and convenient. Today, technology has become…

BySenior EditorAugust 9, 2022

INSIGHTS+

Top Performing Drug of 2021 – Keytruda (May Edition)

Active Ingredients: Pembrolizumab Strength: 100 mg/4 mL (25 mg/mL) Dosage Form: Syringe, Vial Mechanism of Action: PD-1 ligands antagonists First Approval: US (Sep 4, 2014), EU (Jul 17, 2015) Revenue Keytruda (pembrolizumab) has been a key player in Merck & Co. immuno-oncology drugs for the past years – reaching nearly $17B in annual sales in 2021. Despite the dampening impact…

BySenior EditorMay 26, 2022

THOUGHTSPOT

After Effects of Russia – Ukraine Conflict Over Pharma and Life Sciences Industry

Everywhere on TV, social media, digital print or print media we are hearing/ watching how Russia has invaded Ukraine. Russia and Ukraine are at war which is impacting not only both companies but also millions of lives globally. The situation has affected many areas of day-to-day life including a big burden on the healthcare system…

BySenior EditorMarch 2, 2022

VIEWPOINTS

PharmaShots Interview: Genmab’s Jan van de Winkel Shares Insight on the Tivdak (tisotumab vedotin-tftv) for the Treatment of Recurrent or Metastatic Cervical Cancer

In an interview with PharmaShots, Jan van de Winkel, co-founder, President, and CEO at Genmab shared his views on the US FDA's Accelerated Approval of Tivdak (tisotumab vedotin-tftv) for the Treatment of Recurrent or Metastatic Cervical Cancer Shots: Genmab and Seagen have reported the US FDA's accelerated approval which is based on the P-II innovaTV 204 clinical trials evaluating tisotumab vedotin in…

BySenior EditorNovember 15, 2021

INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2021

The first quarter of 2021 highlights new approvals, M&A, and the clinical data of COVID-19 vaccines. The companies expand their working in COVID-19 by targeting South African & Brazil variants along with other emerging variants Starting with the latest acquisition, Amgen acquired Five Prime for $1.9B, Jazz acquired JW while Boston acquired Preventice. This quarter…

ByRidhi RastogiApril 4, 2021

THOUGHTSPOT

COVID-19 – Where Does The Pharmaceutical Industry Go From Here?

With the race to develop an effective vaccine becoming intense, how has the coronavirus pandemic changed the pharmaceutical industry, and what can we expect in the long- and short-term? Let's see. The year 2020, and the new decade as a whole, has definitely got off to the worst possible start and we have a pandemic…

BySenior EditorSeptember 28, 2020

Top Performing Drug of 2021 – Xarelto (November Edition)

Neurological Clinical Trial Trends Under Pandemic and Changing Geopolitics

Top Performing Drug of 2021 – Stelara (August Edition)

The Emergence of Artificial Intelligence in the Pharmaceutical Industry

Top Performing Drug of 2021 – Keytruda (May Edition)

After Effects of Russia – Ukraine Conflict Over Pharma and Life Sciences Industry

PharmaShots Interview: Genmab’s Jan van de Winkel Shares Insight on the Tivdak (tisotumab vedotin-tftv) for the Treatment of Recurrent or Metastatic Cervical Cancer

PharmaShots’ Key Highlights of First Quarter 2021

COVID-19 – Where Does The Pharmaceutical Industry Go From Here?

Contact US

FOLLOW US